Amarin Corp PLC ADR
Closed
0.61 -3.17
Overview
Share price change
24h
Min
0.59
Max
0.66
Income | 11M 1.5M |
|---|---|
Sales | 11M 67M |
EPS | 0.01 |
Profit margin | 2.252 |
EBITDA | 13M 237K |
Recommendations | Sell |
|---|---|
12 Months Forecast | +72.41 upside |
Next Earnings | 30 Oct 2024 |
|---|
Market Cap | -18M 237M |
|---|---|
Previous open | 3.78 |
Previous close | 0.61 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Amarin Corp PLC ADR Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Amarin Corp PLC ADR Forecast
Price Target
By TipRanks
72.41% upside
12 Months Forecast
Average 1 USD 72.41%
High 1 USD
Low 1 USD
Based on 2 Wall Street analysts offering 12 month price targets forAmarin Corp PLC ADR - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Amarin Corp PLC ADR
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
